Management of Adult Acute Lymphoblastic Leukemia

Hagop M. Kantarjian(The University of Texas MD Anderson Cancer Center), Elias Jabbour(The University of Texas MD Anderson Cancer Center), Ibrahim Aldoss(City of Hope)

JAMA Oncology

May 1, 2025

10.1001/jamaoncol.2025.0613

Cited by 15

Related Papers

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

|Blood|2017|1.5k

Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML

|New England Journal of Medicine|2018|1.4k

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study

|The Lancet Oncology|2014|1.3k

Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy

|Blood|1997|1.2k

Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia

|Journal of Clinical Oncology|2005|951